Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 24, 2011

UK switches HPV vaccine supplier

The UK will switch to using Merck's Gardasil vaccine instead of GlaxoSmithKline's rival product Cervarix to prevent girls from contracting the HPV virus, which can cause cervical cancer.

The UK will switch to using Merck’s Gardasil vaccine instead of GlaxoSmithKline’s rival product Cervarix to prevent girls from contracting the HPV virus, which can cause cervical cancer.

Sanofi Pasteur MSD, a joint venture between Merck and French drug maker Sanofi, won the bid to supply the vaccine in the next school year in a competitive tendering process, the Department of Health announced yesterday.

GlaxoSmithKline, whose vaccine was introduced into the national immunisation programme in September 2008 for girls aged 12-13, opted not to bid in the process because the government had made clear it wanted a vaccine offering broader protection.

Gardasil protects against the two strains of HPV virus that cause more than 70% of cervical cancer in England, and two other strains of the bug that cause 90% of genital warts.

Cervarix prevents the contraction of the two cancer strains only.

The government’s director of immunisation Professor David Salisbury said, "It’s not unusual for the NHS to change vaccines or other medicines – it can happen following competitive tendering exercises or when new research findings come to light.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

"We have one of the best HPV vaccination programmes in the world and we want that success to continue. It will be tremendous to see rates of cervical cancer falling."

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy